Clusterin: a key player in cancer chemoresistance and its inhibitionSystematic review of dasatinib in chronic myeloid leukemiaTamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selectionProfile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemiaEpigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidineDouble siRNA-targeting of cIAP2 and LIVIN results in synergetic sensitization of HCT-116 cells to oxaliplatin treatmentCTLA-4 blockade: therapeutic potential in cancer treatmentsAn update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesEmerging concepts in pancreatic cancer medicine: targeting the tumor stromaPotential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemiaUpdate on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphomaProfile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemiaImmune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatmentPD-L1 expression in human cancers and its association with clinical outcomesRole of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedFunctions and mechanisms of long noncoding RNAs in lung cancerEndocannabinoid system as a regulator of tumor cell malignancy - biological pathways and clinical significanceSalvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesisPostoperative radiation in esophageal squamous cell carcinoma and target volume delineationTargeted therapy for localized non-small-cell lung cancer: a reviewClinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinomaEmerging role of sphingosine-1-phosphate signaling in head and neck squamous cell carcinomaThe evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinibIntrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutationsMeta-analysis of associations of interleukin-28B polymorphisms rs8099917 and rs12979860 with development of hepatitis virus-related hepatocellular carcinomaDelineation of radiation therapy target volumes for patients with postoperative glioblastoma: a reviewProfile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancerDabrafenib: a new opportunity for the treatment of BRAF V600-positive melanomaEmerging treatment options for myelofibrosis: focus on pacritinibOncolytic viruses as immunotherapy: progress and remaining challengesComparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysisIrreversible electroporation: state of the artTargeting gastrointestinal stromal tumors: the role of regorafenibOnivyde for the therapy of multiple solid tumorsIdelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potentialAdvances of wogonin, an extract from Scutellaria baicalensis, for the treatment of multiple tumorsComparative effects of different enteral feeding methods in head and neck cancer patients receiving radiotherapy or chemoradiotherapy: a network meta-analysisRecent advancements in erythrocytes, platelets, and albumin as delivery systemsClinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor
P1433
Q24567925-B53C9759-A5D8-4237-8C30-2D97E5E6284EQ24596026-DDE3D692-C066-4D7E-9160-D59340EE9589Q24605762-AE2DAF31-0ED6-4931-977C-9E56BAE042E1Q24607114-E929C6E8-F047-4854-8BFE-0EDCE4151CBDQ24608659-1F4EBE10-9555-4CD1-BB68-B443BADA04C3Q24614587-C649A293-30F2-4889-928E-449D0F027815Q24622666-7739FC56-DD92-4993-8278-63D9173379E9Q24622700-77EC226B-AE57-4965-9B9C-2D0C2A1C7166Q24627664-9C068DE3-7E39-47E0-908A-F737CDBA278EQ24629908-C7227A2A-A53A-4662-B09C-3061C145F793Q24633710-3BAF8469-92F8-4091-A4B7-487E699DD53AQ24633723-E47FB2E8-C0B3-4563-AD7E-6F4F5ED90033Q26738359-A36DEC6D-9369-47D2-A845-CCE983E8E0E6Q26738361-A9F769BC-F769-49E9-9228-3F7DE05D6772Q26738514-A54B9AE3-FA1A-499C-85D6-D32436C65319Q26738672-83001BF5-106A-4AE6-A23A-33154939B7D8Q26739831-5EB3124C-D44C-4F4C-8985-D73CDD7FC4BDQ26740359-FB43301A-6AED-4BE2-8F91-13EDFCCCFD18Q26740812-B0F40B6D-8F1F-482B-8951-5239BC6E5F8FQ26741018-D37EFBD2-3AB6-4697-B9C5-1B090A7153FCQ26741441-D04946E9-1FE3-4148-8325-30988D265844Q26741530-8946C3EF-820C-4C25-95C9-F56A3FF5FB52Q26744051-508D62AE-F512-431C-9184-DAF011F97394Q26744335-94EE0B06-15B7-41E1-95DE-F4C857966ACAQ26744339-50D15082-7935-4FAB-BC17-4CEE0BB38B3BQ26745585-A336F4AE-4558-4B8C-A791-3C647FC7B4E7Q26745588-DD88F7DE-C16E-4926-97D9-A6125C3D2918Q26745590-0EA08F5C-B10F-4156-9C5B-379B5063E8C5Q26745933-87E9E3CE-E9EC-423D-8989-5A90E49C0928Q26745939-DA73AAEE-3B27-4CE7-831E-2A98528BE96DQ26745942-B22D9157-A59F-4733-8EA3-ABF8C97DCB09Q26746200-461BD177-A9E8-4908-85E5-279C19E3FC82Q26746226-394F3E29-6BA8-4AE2-BE85-A8604E141962Q26747162-CA3D6822-52A8-4D0D-B483-864CA0980B90Q26747166-AEE0C829-C45C-4FCB-9F35-9C3C9FED57A9Q26747753-CEF775D5-C32C-49A5-90EA-B105ED38D786Q26747756-32BE1938-2605-4896-923D-63EEEB8933D3Q26747760-D1476028-F14D-412B-BBFD-194C57475CB3Q26747764-893F04B9-1B34-41DC-A23F-6A5C6081A1ACQ26747768-11C8D583-BBC9-45DE-AEB4-4B7CD7663DFB
P1433
description
begutachtete wissenschaftliche Zeitschrift
@de
peer-reviewed scientific journal
@en
revista científica
@es
revue scientifique
@fr
rivista scientifica
@it
vědecký časopis
@cs
wetenschappelijk tijdschrift van Dove Medical Press
@nl
рецензований науковий журнал
@uk
वैज्ञानिक पत्रिका
@hi
name
OncoTargets and Therapy
@ast
OncoTargets and Therapy
@de
OncoTargets and Therapy
@en
OncoTargets and Therapy
@es
OncoTargets and Therapy
@fr
OncoTargets and Therapy
@it
OncoTargets and Therapy
@nl
type
label
OncoTargets and Therapy
@ast
OncoTargets and Therapy
@de
OncoTargets and Therapy
@en
OncoTargets and Therapy
@es
OncoTargets and Therapy
@fr
OncoTargets and Therapy
@it
OncoTargets and Therapy
@nl
prefLabel
OncoTargets and Therapy
@ast
OncoTargets and Therapy
@de
OncoTargets and Therapy
@en
OncoTargets and Therapy
@es
OncoTargets and Therapy
@fr
OncoTargets and Therapy
@it
OncoTargets and Therapy
@nl
P31
P243
P3181
P4616
P1055
P1058
P1156
19700175000
P1160
Onco Targets Ther.
P1277
P1476
OncoTargets and Therapy
@en